clean-label protein glp-1 compliant food lines Bundle No subscription required. Food companies are targeting users

CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity

However, the study did not include people who made lifestyle changes on their own, such as joining a gym or weight-loss programs

Methods Leveraging the target trial emulation framework, we conducted a retrospective study using observational data to emulate a new user, active comparator trial examining the effects of initiating GLP-1RA (exposure group) versus SGLT2 inhibitors (control group), with random treatment assignment emulated by propensity score matching with 1:1 ratio

J.MoothaV

No crash

Strong Trustpilot reputation